Analyzing Vyant Bio (OTCMKTS:VYNT) and Fortrea (NASDAQ:FTRE)

Vyant Bio (OTCMKTS:VYNT) and Fortrea (NASDAQ:FTRE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Vyant Bio and Fortrea, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyant Bio	0	0	0	0	N/A
Fortrea	1	3	4	0	2.38

Fortrea has a consensus price target of $37.29, suggesting a potential upside of 5.03%. Given Fortrea’s higher possible upside, analysts plainly believe Fortrea is more favorable than Vyant Bio.

Profitability

This table compares Vyant Bio and Fortrea’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vyant Bio	-3,474.81%	-151.82%	-97.14%
Fortrea	N/A	N/A	N/A

Earnings & Valuation

This table compares Vyant Bio and Fortrea’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyant Bio	$670,000.00	1.83	-$22.69 million	N/A	N/A
Fortrea	$3.11 billion	1.02	-$3.40 million	N/A	N/A

Fortrea has higher revenue and earnings than Vyant Bio.

Summary

Fortrea beats Vyant Bio on 7 of the 8 factors compared between the two stocks.

About Vyant Bio

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.

About Fortrea

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.